Ведение пациентов пожилого возраста с остеоартритом (Методические рекомендации Российской ассоциации геронтологов и гериатров)

В клинических рекомендациях отражены особенности ведения остеоартрита у пациентов пожилого возраста. Обсуждается высокая распространенность коморбидности у этой категории пациентов, связь остеоартрита и гериатрических синдромов, таких как старческая астения, саркопения. Подчеркивается высокая распространенность невропатической боли у пациентов пожилого возраста с остеоартритом. Все эти особенности предполагают оптимизацию не- и медикаментозной терапии.

1. Наумов А. В., Воробьёва Н. М., Ховасова Н. О., Мороз В. И., Мешков А. Д., Маневич Т. М., Ткачева О. Н., Котовская Ю. В., Селезнева Е. В., Овчарова Л. Н. Распространенность остеоартрита и его ассоциации с гериатрическими синдромами у лиц старше 65 лет: данные российского эпидемиологического исследования ЭВКАЛИПТ // Терапевтический архив. — 2021 — Т. 93, № 12. — С. 1485–1493 doi: 10.26442/00403660.2021.12.201268.

2. Veronese N., Honvo G., Bruyère O., et al. Knee osteoarthritis and adverse health outcomes: an umbrella review of meta-analyses of observational studies. Aging Clin Exp Res. 2023 ; 35 (2) : 245–252. doi: 10.1007/s40520-022-02289-4.

3. Ritsuno, Y., Kawado, M., Morita, M. et al. Impact of musculoskeletal disorders on healthy life expectancy in Japan. BMC Musculoskelet Disord. 2021 ; 22 : 661. doi: 10.1186/s12891-021-04539-4.

4. Liao J., Yu X., Chen J., Wu Z., He Q., Zhang Y., Song W., Luo J., Tao Q. Knowledge mapping of autophagy in osteoarthritis from 2004 to 2022: A bibliometric analysis. Front Immunol. 2023 ; 14 : 1063018. doi: 10.3389/fimmu.2023.1063018.

5. Musumeci G., Castrogiovanni P., Trovato F. M., et al.. Microscopic and macroscopic anatomical features in healthy and osteoarthritic knee cartilage. OA Anatomy. 2013 ; 1 (3) : 30. doi: 10.13172/2052-7829-1-3-898.

6. Ramasamy T. S., Yee Y. M., Khan I. M. Chondrocyte Aging: The Molecular Determinants and Therapeutic Opportunities. Frontiers in Cell and Developmental Biology. 2021 ; 9 : 625497. doi: 10.3389/fcell.2021.625497.

7. Korochina K. V., Chernysheva T. V., Korochina I. E. Clinical manifestations, histopathological changes and quality of life in patients with advanced knee osteoarthritis caused by age, trauma, obesity and their combination. Russian Open Medical Journal. 2021 ; 10 (3) : e0312. doi: 10.15275/rusomj.2021.0312.

8. Swain S., Sarmanova A., Coupland C., Doherty M., Zhang W. Comorbidities in Osteoarthritis: A Systematic Review and Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2020 ; 72 (7) : 991–1000. doi: 10.1002/acr.24008.

9. Leyland, K. M., Gates, L. S., Sanchez-Santos, M. T. et al. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: an international meta-analysis of individual participant-level data. Aging Clin Exp Res. 2021 ; 33 : 529–545. doi: 10.1007/s40520-020-01762-2.

10. Lindéus M., Turkiewicz A., Englund M., Kiadaliri A. Socioeconomic inequalities in all-cause and cause-specific mortality among patients with osteoarthritis in the Skåne region of Sweden. Arthritis Care Res. 2022 ; 74 (10) : 1704–1712. doi: 10.1002/acr.24613.

11. Constantino de Campos G., Mundi R., Whittington C., et al. Osteoarthritis, mobility-related comorbidities and mortality: an overview of meta-analyses. Ther Adv Musculoskelet Dis. 2020 ; 12 : 1759720X20981219. doi: 10.1177/1759720X20981219.

12. Liu W., Ma W., Liu H., Li C., Zhang Y., Liu J., et al. Stroke risk in arthritis: A systematic review and meta-analysis of cohort studies. PLoS One. 2021 ; 16 (3) : e0248564. doi: 10.1371/journal.pone.0248564.

13. Valdes, Ana & Stocks, Joanne. (2018). Osteoarthritis and Ageing. EMJ. 2018 ; 3 (1) : 116–123. doi: 10.33590/emj/10313855.

14. Cacciatore F., Della-Morte D., Basile C., Mazzella F., Mastrobuoni C., Salsano E., Gargiulo G., Galizia G., Rengo F., Bonaduce D., Abete P. Long-term mortality in frail elderly subjects with osteoarthritis. Rheumatology (Oxford). 2014 ; 53 (2) : 293–9299. doi: 10.1093/rheumatology/ket348.

15. Doré A. L., Golightly Y. M., Mercer V. S., et al. Lowerextremity osteoarthritis and the risk of falls in a community-based longitudinal study of adults with and without osteoarthritis. Arthritis Care Res (Hoboken). 2015 ; 67 (5) : 633–639. doi: 10.1002/acr.22499.

16. Veronese N., Stubbs B., Solmi M., et al. Association between lower limb osteoarthritis and incidence of depressive symptoms: data from the osteoarthritis initiative. Age and Ageing. 2017 ; 46 (3) : 470–476. doi: 10.1093/ageing/afw216.

17. Yamada K., Kubota Y., Tabuchi T., et al. A prospective study of knee pain, low back pain, and risk of dementia: the JAGES project. Sci Rep. 2019 ; 9 (1) : 10690. doi: 10.1038/s41598-019-47005-x.

18. Hanlon P., Nicholl B. I., Jani B. D., et al. Frailty and prefrailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018 ; 3 (7) : e323–e332. doi: 10.1016/S2468-2667(18)30091-4.

19. Hoops M., Rosenblatt N., Hurt C., et al. Does lower extremity osteoarthritis exacerbate risk factors for falls in older adults? Womens Health (Lond). 2012 ; 8 (6) : 685–698. doi: 10.2217/whe.12.53.

20. Barbour K. E., Stevens J. A., Helmick C. G., et al. Falls and fall injuries among adults with arthritis–United States, 2012. MMWR Morb Mortal WklyRep. 2014 ; 63 (17) : 379–383.

21. Hana S., Aicha B. T., Selim D., et al. Clinical and Radiographic Features of Knee Osteoarthritis of Elderly Patients. Curr Rheumatol Rev. 2018 ; 14 (2) : 181–187. doi: 10.2174/1573397113666170425150133.

22. Nikolic G., Nedeljkovic B., Trajkovic G., et al. Pain, Physical Function, Radiographic Features, and Quality of Life in Knee Osteoarthritis Agricultural Workers Living in Rural Population. Pain Res Manag. 2019 ; 2019 : 7684762. doi: 10.1155/2019/7684762.

23. Foley S. J., Lord S. R., Srikanth V., et al. Falls risk is associated with pain and dysfunction but not radiographic osteoarthritis in older adults: Tasmanian Older Adult Cohort study. Osteoarthritis Cartilage. 2006 ; 14 (6) : 533–539. doi: 10.1016/j.joca.2005.12.007.

24. De Ceuninck F., Fradin A., Pastoureau P. Bearing arms against osteoarthritis and sarcopenia: when cartilage and skeletal muscle find common interest in talking together. Drug Discov Today. 2014 ; 19 (3) : 305–311. doi: 10.1016/j.drudis.2013.08.004.

25. Alexandre T. d. S., Duarte Y. A. O., Santos J. L. F., Lebrão M. L. Prevalence and associated factors of sarcopenia, dynapenia, and sarcodynapenia in community-dwelling elderly in São Paulo — SABE Study. Rev Bras Epidemiol. 2019 ; 21 Suppl 02 (Suppl 02) : e180009. Portuguese, English. doi: 10.1590/1980-549720180009.supl.2.

26. Lee K., Shin Y., Huh J., et al. Recent Issues on Body Composition Imaging for Sarcopenia Evaluation. Korean J Radiol. 2019 ; 20 (2) : 205–217. doi: 10.3348/kjr.2018.0479.

27. Pedersen B. K., Fischer C. P. Beneficial health effects of exercise — the role of IL-6 as a myokine. Trends Pharmacol Sci. 2007; 28 (4) : 152–156. doi: 10.1016/j.tips.2007.02.002.

28. Kelly M., Gauthier M. S., Saha A. K., Ruderman N. B. Activation of AMP-activated protein kinase by interleukin-6 in rat skeletal muscle: association with changes in cAMP, energy state, and endogenous fuel mobilization. Diabetes. 2009 ; 58 (9 ): 1953–1960. doi: 10.2337/db08-1293.

29. Morley J. E. Sarcopenia in the elderly. Fam Pract. 2012 ; 29 (suppl. 1): i44–i48. doi: 10.1093/fampra/cmr063.

30. Sampson E. L., White N., Lord K., et al. Pain, agitation, and behavioural problems in people with dementia admitted to general hospital wards: a longitudinal cohort study. Pain. 2015 ; 156 (4) : 675–683. doi: 10.1097/j.pain.0000000000000095.

31. Rajkumar A. P., Ballard C., Fossey J., et al. Epidemiology of Pain in People With Dementia Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications. J Am Med Dir Assoc. 2017 ; 18 (5) : 453.e1–453.e6. doi: 10.1016/j.jamda.2017.01.024.

32. Meraya A. M., Dwibedi N., Sambamoorthi U. Polypharmacy and Health-Related Quality of Life Among US Adults With Arthritis, Medical Expenditure Panel Survey, 2010–2012. Prev Chronic Dis. 2016 ; 13 : E132. doi: 10.5888/pcd13.160092.

33. Whitlock E. L., Diaz-Ramirez L. G., Glymour M. M., et al. Association Between Persistent Pain and Memory Decline and Dementia in a Longitudinal Cohort of Elders. JAMA Intern Med. 2017 ; 177 (8) : 1146–1153. doi: 10.1001/jamainternmed.2017.1622.

34. Pitcher M. H., Von Korff M., Bushnell M. C., Porter L. Prevalence and Profile of High-Impact Chronic Pain in the United States. J Pain. 2019 ; 20 (2) : 146–160. doi: 10.1016/j.jpain.2018.07.006.

35. Macfarlane G. J., Barnish M. S., Jones G. T. Persons with chronic widespread pain experience excess mortality: longitudinal results from UK Biobank and meta-analysis. Ann Rheum Dis. 2017 ; 76 (11) : 1815–1822. doi: 10.1136/annrheumdis-2017-211476.

36. Ensrud K. E., Ewing S. K., Cawthon P. M., et al. A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men. J Am Geriatr Soc. 2009 ; 57 (3) : 492–498. doi: 10.1111/j.1532-5415.2009.02137.x.

37. Felson D. T., Niu J., Yang T., et al. Physical activity, alignment and knee osteoarthritis: data from MOST and the OAI. Osteoarthritis Cartilage. 2013 ; 21 (6) : 789–795. doi: 10.1016/j.joca.2013.03.001.

38. Misra D., Felson D. T., Silliman R. A., et al. Knee osteoarthritis and frailty: findings from the Multicenter Osteoarthritis Study and Osteoarthritis Initiative. J Gerontol A Biol Sci Med Sci. 2015 ; 70 (3) : 339–344. doi: 10.1093/gerona/glu102.

39. McGuigan F. E., Bartosch P., Åkesson K. E. Musculoskeletal health and frailty. Best Pract Res Clin Rheumatol. 2017 ; 31 (2) : 145–159. doi: 10.1016/j.berh.2017.11.002.

40. Nakamura K. A «super-aged» society and the «locomotive syndrome». J Orthop Sci. 2008 ; 13 (1) : 1–2. doi: 10.1007/s00776-007-1202-6.

41. Ogata T., Muranaga S., Ishibashi H., et al. Development of a screening program to assess motor function in the adult population: a cross-sectional observational study. J Orthop Sci. 2015 ; 20 (5) : 888–895. doi: 10.1007/s00776-015-0737-1.

42. Yoshimura N., Oka H., Muraki S., et al. Reference values for hand grip strength, muscle mass, walking time, and one-leg standing time as indices for locomotive syndrome and associated disability: the second survey of the ROAD study. Journal of Orthopaedic Science. 2011 ; 16: 768–777. doi: 10.1007/s00776-011-0160-1.

43. Kimura A., Seichi A., Konno S., et al. Prevalence of locomotive syndrome in Japan: a nationwide, cross-sectional Internet survey. J Orthop Sci. 2014 ; 19 (5) : 792–797. doi: 10.1007/s00776-014-0606-3.

44. Yoshimura N., Muraki S., Nakamura K., Tanaka S. Epidemiology of the locomotive syndrome: The research on osteoarthritis/osteoporosis against disability study 2005–2015. Mod Rheumatol. 2017 ; 27 (1) : 1–7. doi: 10.1080/14397595.2016.1226471.

45. The outline of the results of National Livelihood Survey 2013. Ministry of Health, Labour, and Welfare [of Japan]. Электрон. дан. (In Japanese.). [Электронный ресурс]. Available at: https://www.mhlw.go.jp/toukei/saikin/hw/k-tyosa/k-tyosa13/dl/06.pdf.

46. Jiang T., Yang T., Zhang W., et al. Prevalence of ultrasound-detected knee synovial abnormalities in a middle-aged and older general population — the Xiangya Osteoarthritis Study. Arthritis Res Ther. 2021 ; 23 (1) : 156. doi: 10.1186/s13075-021-02539-2.

47. Thakur M., Dickenson A. H., Baron R. Osteoarthritis pain: nociceptive or neuropathic? Nat Rev Rheumatol. 2014 ; 10 (6) : 374–380. doi: 10.1038/nrrheum.2014.47.

48. Наумов А. В., Воробьёва Н. М., Ховасова Н. О., Ткачева О. Н., Котовская Ю. В., Селезнева Е. В., Овчарова Л. Н. Особенности гериатрического статуса у пожилых пациентов с остеоартритом в сочетании с невропатической болью: данные российского эпидемиологического исследования ЭВКАЛИПТ. // Современная ревматология. — 2022. — Т. 16, № 3. — С. 50–59. doi: 10.14412/1996-7012-2022-3-50-59.

49. Xiao Q., Cai B., Yin A., et al. L-shaped association of serum 25-hydroxyvitamin D concentrations with cardiovascular and all-cause mortality in individuals with osteoarthritis: results from the NHANES database prospective cohort study. BMC Med. 2022 ; 20 (1) : 308. doi: 10.1186/s12916-022-02510-1.

50. Poisbeau P., Aouad M., Gazzo G., et al. Cholecalciferol (Vitamin D3) Reduces Rat Neuropathic Pain by Modulating Opioid Signaling. Mol Neurobiol. 2019 ; 56 (10) : 7208–7221. doi: 10.1007/s12035-019-1582-6.

51. Shipton E. A., Shipton E. E. Vitamin D and Pain: Vitamin D and Its Role in the Aetiology and Maintenance of Chronic Pain States and Associated Comorbidities. Pain Res Treat. 2015 ; 2015 : 904967. doi: 10.1155/2015/904967.

52. Zadro J., Shirley D., Ferreira M., et al. Mapping the Association between Vitamin D and Low Back Pain: A Systematic Review and Meta-Analysis of Observational Studies. Pain Physician. 2017 ; 20 (7) : 611–640.

53. Wu Z., Malihi Z., Stewart A. W., Lawes C. M., Scragg R. The association between vitamin D concentration and pain: a systematic review and meta-analysis. Public Health Nutr. 2018 ; 21 (11) : 2022–2037. doi: 10.1017/S1368980018000551.

54. Chew S. T. H., Kayambu G., Lew C. C. H., et al. Singapore multidisciplinary consensus recommendations on muscle health in older adults: assessment and multimodal targeted intervention across the continuum of care. BMC Geriatr. 2021 ; 21 (1) : 314. doi: 10.1186/s12877-021-02240-8.

55. Shipton E. E., Shipton E. A. Vitamin D Deficiency and Pain: Clinical Evidence of Low Levels of Vitamin D and Supplementation in Chronic Pain States. Pain Ther. 2015 ; 4 (1) : 67–87. doi: 10.1007/s40122-015-0036-8.

56. Mohamed Y., Haifa H., Datel O., et al. Intérêt des marqueurs du remodelage osseux dans le diagnostic de l'ostéoporose et la prediction du risqué de fracture [The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk]. Tunis Med. 2014 ; 92 (5) : 304–310. French.

57. Hadjistavropoulos T., Herr K., Turk D. C., et al. An interdisciplinary expert consensus statement on assessment of pain in older persons. Clin J Pain. 2007 ; 23 (1 Suppl) : S1–43. doi: 10.1097/AJP.0b013e31802be869.

58. Abdulla A., Adams N., Bone M., Elliott A.M., Gaffin J., Jones D., et al. Guidance on the management of pain in older people. Age Ageing. 2013 ; 42 Suppl 1 : i1–57. doi: 10.1093/ageing/afs200.

59. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009 ; 57 (8) : 1331–1346. doi: 10.1111/j.1532-5415.2009.02376.x.

60. Ali S., Garcia J. M. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options — a mini-review. Gerontology. 2014 ; 60 (4) : 294–305. doi: 10.1159/000356760.

61. Gillespie L. D., Robertson M. C., Gillespie W. J., et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012.9. doi: 10.1002/14651858.CD007146.pub2.

62. Turner S., Arthur G., Lyons R. A., et al. Modification of the home environment for the reduction of injuries. Cochrane Database Syst Rev. 2011 ; 2011 (2) : CD003600. doi: 10.1002/14651858.CD003600.pub3.

63. Cumming R. G., Thomas M., Szonyi G., et al. Home visits by an occupational therapist for assessment and modification of environmental hazards: a randomized trial of falls prevention. J Am Geriatr Soc. 1999 ; 47 (12) : 1397–1402. doi: 10.1111/j.1532-5415.1999.tb01556.x.

64. Calvani R., Miccheli A., Landi F., et al. Current nutritional recommendations and novel dietary strategies to manage sarcopenia. J Frailty Aging. 2013 ; 2 (1) : 38–53.

65. Symons T. B., Sheffield-Moore M., Wolfe R. R., Paddon-Jones D. A moderate serving of high-quality protein maximally stimulates skeletal muscle protein synthesis in young and elderly subjects. J Am Diet Assoc. 2009 ; 109 (9) : 1582–1586. doi: 10.1016/j.jada.2009.06.369.

66. Kim C. O., Lee K. R. Preventive effect of protein-energy supplementation on the functional decline of frail older adults with low socioeconomic status: a community-based randomized controlled study. J Gerontol A Biol Sci Med Sci. 2013 ; 68 (3) : 309–316. doi: 10.1093/gerona/gls167.

67. You T., Ogawa E. F., Thapa S., et al. Effects of Tai Chi on beta endorphin and inflammatory markers in older adults with chronic pain: an exploratory study. Aging Clin Exp Res. 2020 ; 32 (7) : 1389–1392. doi: 10.1007/s40520-019-01316-1.

68. You T., Ogawa E. F., Thapa S., et al. Tai Chi for older adults with chronic multisite pain: a randomized controlled pilot study. Aging Clin Exp Res. 2018 ; 30 (11) : 1335–1343. doi: 10.1007/s40520-018-0922-0.

69. Li F., Harmer P., Fitzgerald K., et al. Effectiveness of a Therapeutic Tai Ji Quan Intervention vs a Multimodal Exercise Intervention to Prevent Falls Among Older Adults at High Risk of Falling: A Randomized Clinical Trial. JAMA Intern Med. 2018 ; 178 (10) : 1301–1310. doi: 10.1001/jamainternmed.2018.3915.

70. Gatica-Rojas V., Cartes-Velásquez R., Albornoz-Verdugo M. E., et al. Effects of a Nintendo Wii exercise program versus Tai Chi Chuan on standing balance in older adults: a preliminary study. J Phys Ther Sci. 2019 ; 31 (1) : 1–4. doi: 10.1589/jpts.31.1.

71. Qi M., Moyle W., Jones C., Weeks B. Tai Chi Combined With Resistance Training for Adults Aged 50 Years and Older: A Systematic Review. J Geriatr Phys Ther. 2020 ; 43 (1) : 32–41. doi: 10.1519/JPT.0000000000000218.

72. Bannuru R. R., Osani M. C., Vaysbrot E. E., et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 ; 27 (11) : 1578–1589. doi: 10.1016/j.joca.2019.06.011.

73. Ali A., Arif A. W., Bhan C., et al. Managing Chronic Pain in the Elderly: An Overview of the Recent Therapeutic Advancements. Cureus. 2018 ; 10 (9) : e3293. doi: 10.7759/cureus.3293.

74. Knopp-Sihota J. A., MacGregor T., Reeves J. T. H., et al. Management of Chronic Pain in Long-Term Care: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2022 ; 23 (9) : 1507–1516.e0. doi: 10.1016/j.jamda.2022.04.008.

75. Bhala N., Emberson J., Merhi A., Abramson S., et al. Vascular and upper gastrointestinal effects of non-steroidal antiinflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 ; 382 (9894) : 769–779. doi: 10.1016/S0140-6736(13)60900-9.

76. Fukuda K., Miyamae F., Tomita K., et al. Association between chronic kidney disease and synergistic, potentially nephrotoxic medication use in elderly hospitalized patients: A single-center cross-sectional study. Int J Clin Pharmacol Ther. 2019 ; 57 (7) : 353–361. doi: 10.5414/CP203429.

77. Schjerning Olsen A. M., Gislason G. H., McGettigan P., et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015 ; 313 (8) : 805–814. doi: 10.1001/jama.2015.0809.

78. Lo-Ciganic W. H., Floden L., Lee J. K., et al. Analgesic use and risk of recurrent falls in participants with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2017 ; 25 (9) : 1390–1398. doi: 10.1016/j.joca.2017.03.017.

79. Dong Y. H., Chang C. H., Wu L. C., et al. Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study. Br J Clin Pharmacol. 2018 ; 84 (5) : 1045–1056. doi: 10.1111/bcp.13537.

80. Yuan J. Q., Tsoi K. K., Yang M. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016 ; 43 (2) : 1262–1275. doi: 10.1111/apt.13642.

81. Derry S., Wiffen P. J., Moore R. A., Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014 ; 2014 (7) : CD010958. doi: 10.1002/14651858.CD010958.pub2.

82. Pickering G., Martin E., Tiberghien F., Delorme C., Mick G. Localized neuropathic pain: an expert consensus on local treatments. Drug Des Devel Ther. 2017 ; 11 : 2709–2718. doi: 10.2147/DDDT.S142630.

83. de León-Casasola O. A., Mayoral V. The topical 5 % lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence. J Pain Res. 2016 ; 9 : 67–79. doi: 10.2147/JPR.S99231.

84. Galicia-Castillo M., Weiner D. K. Treatment of persistent pain in older adults. In: Schmader K. E, ed. UpToDate. Waltham, MA: UpToDate; 2018. www.uptodate.com.

85. Moore R. A., Straube S., Wiffen P. J., et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009 ; (3) : CD007076. doi: 10.1002/14651858.CD007076.pub2.

86. Reisner L. Pharmacological management of persistent pain in older persons. J Pain. 2011 ; 12 (3 Suppl 1) : S21–29. doi: 10.1016/j.jpain.2011.01.001.

87. Snedecor S. J., Sudharshan L., Cappelleri J. C., et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014 ; 68 : 900–918. doi: 10.1111/ijcp.12411.

88. Oneschuk D., al-Shahri M. Z. The pattern of gabapentin use in a tertiary palliative care unit. J Palliat Care. 2003 ; 19 : 185–187.

89. Wiffen P. J., Derry S., Bell R. F., et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017 ; 6 (6) : CD007938. doi: 10.1002/14651858.CD007938.pub4.

90. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005 ; 116 (1–2) : 109–118. doi: 10.1016/j.pain.2005.03.029.

91. Sindrup S. H., Otto M., Finnerup N. B., Jensen T. S. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol. 2005 ; 96 (6) : 399–409. doi: 10.1111/j.1742-7843.2005.pto_96696601.x.

92. Finnerup N. B., Attal N., Haroutounian S., et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 ; 14 (2) : 162–173. doi: 10.1016/S1474-4422(14)70251-0.

93. Mu A., Weinberg E., Moulin D. E., Clarke H. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Can Fam Physician. 2017 ; 63 (11) : 844–852.

94. Dworkin R.H., O’Connor A.B., Audette J., et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010 ; 85 (3) : 3–14. doi: 10.4065/mcp.2009.0649.

95. NHMRC. Guidelines for the pharmacological treatment of neuropathic pain Australian Clinical Practice Guidelines. [Электронный ресурс] Available at: https://www.clinicalguidelines.gov.au/portal/2290/guidelines-treatment-neuropathic-pain. 2018.

96. Tarride J. E., Collet J. P., Choiniere M., Rousseau C., Gordon A. The economic burden of neuropathic pain in Canada. J Med Econ. 2006 ; 9 (1–4) : 55–68. doi: 10.3111/200609055068.

97. Cipriani A., Koesters M., Furukawa T. A., et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012 ; 10 (10) : CD006533. doi: 10.1002/14651858.CD006533.pub2.

98. Everitt H., Baldwin D. S., Stuart B., et al. Antidepressants for insomnia in adults. Cochrane Database Syst Rev. 2018 ; 5 (5) : CD010753. doi: 10.1002/14651858.CD010753.pub2.

99. O'Malley P. G., Balden E., Tomkins G., et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000 ; 15 (9) : 659–666. doi: 10.1046/j.1525-1497.2000.06279.x.

100. Thorpe J., Shum B., Moore R. A., Wiffen P. J., Gilron I. Combination pharmacotherapy for the treatment of fibromyalgia in adults. Cochrane Database Syst Rev. 2018 ; 2 (2) : CD010585. doi: 10.1002/14651858.CD010585.pub2.

101. Turner B. J., Liang Y. Drug Overdose in a Retrospective Cohort with Non-Cancer Pain Treated with Opioids, Antidepressants, and/or Sedative-Hypnotics: Interactions with Mental Health Disorders. J Gen Intern Med. 2015 ; 30 (8) : 1081–1096. doi: 10.1007/s11606-015-3199-4.

102. Gallagher R. M. Management of neuropathic pain: translating mechanistic advances and evidence-based research into clinical practice. Clin J Pain. 2006 ; 22 (1 Suppl) : S2–8. doi: 10.1097/01.ajp.0000193827.07453.d6.

103. Blazer D., Hybels C., Simonsick E., Hanlon J. T. Sedative, hypnotic, and antianxiety medication use in an aging cohort over ten years: a racial comparison. J Am Geriatr Soc. 2000 ; 48 (9) : 1073–1079. doi: 10.1111/j.1532-5415.2000.tb04782.x.

104. American geriatrics society 2015 updated beers criteria for inappropriate medication use in older adults. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. J Am Geriatr Soc. 2015 ; 63 (11) : 2227–2246. doi: 10.1111/jgs.13702.

105. Furlan A. D., Sandoval J. A., Mailis-Gagnon A., Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006 ; 174 (11) : 1589–1594. doi: 10.1503/cmaj.051528.

106. Nuesch E., Rutjes A. W., Husni E., Welch V., Juni P. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2009 ; (4) : CD003115. doi: 10.1002/14651858.CD003115.pub3.

107. Inacio M. C. S., Cashman K., Pratt N. L., et al. Prevalence and changes in analgesic medication utilisation 1 year prior to total joint replacement in an older cohort of patients. Osteoarthritis Cartilage. 2018 ; 26 (3) : 356–362. doi: 10.1016/j.joca.2017.11.016.

108. Birke H., Kurita G.P., Sjøgren P., Højsted J., et al. Chronic non-cancer pain and the epidemic prescription of opioids in the Danish population: trends from 2000 to 2013. Acta Anaesthesiologica Scandinavica. 2016 ; 60 (5) : 623–633. doi: 10.1111/aas.12700.

109. Volkow N. D., McLellan A. T. Opioid abuse in chronic pain — misconceptions and mitigation strategies. Engl J Med. 2016 ; 374 (13) : 1253–1263. doi: 10.1056/NEJMra1507771.

110. Rizzoli R., Boonen S, Brandi M. L., et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin. 2013 ; 29 (4) : 305–313. doi: 10.1185/03007995.2013.766162.

111. Wu Z., Malihi Z., Stewart A. W., et al. Effect of Vitamin D Supplementation on Pain: A Systematic Review and Meta-analysis. Pain Physician. 2016 ; 19 (7) : 415–427.

112. Mukherjee D., Lahiry S., Thakur S., Chakraborty D. S. Effect of 1,25 dihydroxy vitamin D3 supplementation on pain relief in early rheumatoid arthritis. J Family Med Prim Care. 2019 ; 8 (2) : 517–522. doi: 10.4103/jfmpc.jfmpc_446_18.

113. Cheng O.T., Souzdalnitski D., Vrooman B., Cheng J. Evidence-based knee injections for the management of arthritis. Pain Med. 2012 ; 13 (6) : 740–753. doi: 10.1111/j.1526-4637.2012.01394.x.

114. Charlesworth J., Fitzpatrick J., Perera N. K. P., Orchard J. Osteoarthritis — a systematic review of long-term safety implications for osteoarthritis of the knee. BMC Musculoskelet Disord. 2019 ; 20 (1) : 151. doi: 10.1186/s12891-019-2525-0.

115. Plaas A., Li J., Riesco J., et al. Intraarticular injection of hyaluronan prevents cartilage erosion, periarticular fibrosis and mechanical allodynia and normalizes stance time in murine knee osteoarthritis. Arthritis Res Ther. 2011 ; 13 (2) : R46. doi: 10.1186/ar3286.

116. Honvo G., Reginster J. Y., Rannou F., et al. Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 ; 36 (Suppl 1) : 101–127. doi: 10.1007/s40266-019-00657-w.

117. Trigkilidas D., Anand A. The effectiveness of hyaluronic acid intra-articular injections in managing osteoarthritic knee pain. Ann R Coll Surg Engl. 2013 ; 95 (8) : 545–551. doi: 10.1308/rcsann.2013.95.8.545.

118. Iannitti T., Lodi D., Palmieri B. Intra-articular injections for the treatment of osteoarthritis: focus on the clinical use of hyaluronic acid. Drugs R D. 2011 ; 11 (1) :13–27. doi: 10.2165/11539760-000000000-00000.

119. Bowman S., Awad M. E., Hamrick M. W., et al. Recent advances in hyaluronic acid based therapy for osteoarthritis. Clin Transl Med. 2018 ; 7 (1) : 6. doi: 10.1186/s40169-017-0180-3.

120. Rewald S., Mesters I., Lenssen A. F., et al. Effect of aqua-cycling on pain and physical functioning compared with usual care in patients with knee osteoarthritis: study protocol of a randomised controlled trial. BMC Musculoskelet Disord. 2016 ; 17 : 88. doi: 10.1186/s12891-016-0939-5.

121. Beaudart C., Lengelé L., Leclercq V., et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020 ; 80 (18) : 1947–1959. doi: 10.1007/s40265-020-01423-8.

122. Yang W., Sun C., He S. Q. et al. he Efficacy and Safety of Disease-Modifying Osteoarthritis Drugs for Knee and Hip Osteoarthritis-a Systematic Review and Network Meta-Analysis. J Gen Intern Med. 2021 ; 36 (7) : 2085–2093. doi: 10.1007/s11606-021-06755-z.

123. Pelletier J. P., Raynauld J. P., Dorais M., et al. An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. Rheumatology (Oxford). 2020 ; 59 (12) :3858–3868. doi: 10.1093/rheumatology/keaa072.

124. Liu X., Machado G. C., Eyles J. P., et al. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018 ; 52 (3) : 167–175. doi: 10.1136/bjsports-2016-097333.

125. Kongtharvonskul J., Anothaisintawee T., McEvoy M., et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015 ; 20 (1) : 24. doi: 10.1186/s40001-015-0115-7.

126. Christensen R., Bartels E. M., Astrup A., Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008 ; 16 (4) : 399–408. doi: 10.1016/j.joca.2007.10.003.

127. Maheu E., Cadet C., Marty M., et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014 ; 73 (2) : 376–384. doi: 10.1136/annrheumdis-2012-202485.

128. Dixon A. S, Kersley G. D., Mercer R., et al. A doubleblind controlled trial of Rumalon in the treatment of painful osteoarthrosis of the hip. Ann Rheum Dis. 1970 ; 29 (2) : 193–194. doi: 10.1136/ard.29.2.193-b.

129. V. Rejholec, M. Králová. Langzeitbehandlung der Coxarthrose mit Rumalon®. Akt Rheumatol. 1984 ; 9 (S 2) : 139–148. doi: 10.1055/s-2008-1048133.

130. Gramajo R. J., Cutroneo E. J., Fernandez D. E., et al. A single-blind, placebo-controlled study of glycosaminoglycanpeptide complex ('Rumalon') in patients with osteoarthritis of the hip or knee. Curr Med Res Opin. 1989 ; 11 (6) : 366–373. doi: 10.1185/03007998909110137.

131. Rejholec V. Clinical trials of anti-osteoarthritic agents. Scand J Rheumatol Suppl. 1990 ; 81 : 28–31. doi: 10.3109/03009749009096943.

132. Алексеева Л. И., Карякин А. Н., Смирнов А. В., Беневоленская Л. И. Применение Румалона при гонартрозе. // Терапевтический архив. — 1997. — Т. 69, № 5. — С. 64–66.

133. Pavelká K, Gatterová J, Gollerova V, et al. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000 ; 8 (5) : 335–342. doi: 10.1053/joca.1999.0307.

134. Алексеева Л. И., Шарапова Е. П., Таскина Е. А. и др. Многоцентровое слепое рандомизированное плацебоконтролируемое исследование симптом- и структурно-модифицирующего действия препарата алфлутоп у больных остеоартрозом коленных суставов. Сообщение 2 — оценка структурно-модифицирующего действия препарата. // Научно-практическая ревматология. — 2014. — Т. 52, № 2. — С. 174–177. doi: 10.14412/1995-4484-2014-174-177.

135. Алексеева Л. И., Таскина Е. А., Лила А. М.и др.. Многоцентровое проспективное рандомизированное исследование эффективности и безопасности препарата Алфлутоп® в альтернирующем режиме по сравнению со стандартным режимом. Сообщение 1: оценка эффективности препарата при различных схемах применения. // Современная ревматология. — 2019. — Т. 13, № 3. — С. 51–59. doi: 10.14412/1996-7012-2019-3-51-59.

136. Бердюгин К. А., Кадынцев И. В., Бердюгина О. В. и др. Оценка эффективности и безопасности комбинированной терапии симптоматическим препаратом замедленного действия и гиалуроновой кислотой в сравнении с монотерапией гиалуроновой кислотой у пациентов с остеоартритом коленного сустава. Современная ревматология. — 2020. — Т. 14, № 3. — С. 63–70. doi: 10.14412/1996-7012-2020-3-63-70.

137. Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 ; 49 (3) : 337–350. doi: 10.1016/j.semarthrit.2019.04.008.

138. Navarro S. L., Levy L., Curtis K. R., et al. Modulation of Gut Microbiota by Glucosamine and Chondroitin in a Randomized, Double-Blind Pilot Trial in Humans. Microorganisms. 2019 ; 7 (12) : 610. doi: 10.3390/microorganisms7120610.

139. Hu S., Wang J., Xu Y., et al. Anti-inflammation effects of fucosylated chondroitin sulphate from Acaudina molpadioides by altering gut microbiota in obese mice. Food Funct. 2019 ; 10 (3) : 1736–1746. doi: 10.1039/c8fo02364f.

140. Shmagel A., Demmer R., Knights D., et al. The Effects of Glucosamine and Chondroitin Sulfate on Gut Microbial Composition: A Systematic Review of Evidence from Animal and Human Studies. Nutrients. 2019 ; 11 (2) : 294. doi: 10.3390/nu11020294.

141. Левин О. С., Олюнин Д. Ю., Голубева Л .В. Эффективность алфлутопа при хронической вертеброгенной люмбоишиалгии по данным двойного слепого плацебо-контролируемого исследования. // Научно-практическая ревматология. — 2004. — Т. 42, № 4. — С. 80–84. doi: 14412/1995-4484-2004-809.

142. Nosivets, Dmitriy & V.I., Opryshko. (2019). Systemic review of international studies on the use of Alflutop in the comprehensive pharmacotherapy of back pain = Системный обзор международных исследований по примененияю Алфлутопа в комплексной фармакотерапии болевого синдрома в области спины. International Neurological Journal. 2019 ; 95 (1) : 64–69.

143. Живолупов С. А., Данилов А. Б., Баранцевич Е. Р. и др. Эффективность и безопасность применения препарата Алфлутоп при лечении болевого синдрома в нижней части спины. // Manage Pain. — 2020. — № 1. — С. 41–48.

144. Каратеев А. Е. Биоактивный концентрат мелкой морской рыбы: оценка эффективности и безопасности препарата на основании анализа 37 клинических исследований. // Современная ревматология. — 2020. — Т. 14, № 4. — С. 111–124. doi: 10.14412/1996-7012-2020-4-111-124.

145. Алексеева Л. И., Бельская Г. Н., Каракулова Ю. В. и др. Возможности патогенетического лечения хронической боли в спине. // Manage Pain. — 2018. — № 2. — С. 47–51.

146. Алексеева Л. И., Шарапова Е. П., Кашеварова Н. Г., и др. Применение АРТРА МСМ Форте у пациентов с остеоартрозом коленного сустава: результаты рандомизированного открытого сравнительного изучения эффективности и переносимости препарата. // Терапевтический архив. — 2015. — Т. 87, № 12. — C. 49–54.

147. Jüni P., Reichenbach S., Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol. 2006 ; 20 (4) : 721–740. doi: 10.1016/j.berh.2006.05.002.

148. Barbieri A., Vanhaecht K., Van Herck P., et al. Effects of clinical pathways in the joint replacement: a meta-analysis. BMC Med. 2009 ; 7 (1) : 32. doi: 10.1186/1741-7015-7-32.

149. Gooch K., Marshall D. A., Faris P. D., et al. Comparative effectiveness of alternative clinical pathways for primary hip and knee joint replacement patients: a pragmatic randomized, controlled trial. Osteoarthritis Cartilage. 2012 ; 20 (10) : 1086–1094. doi: 10.1016/j.joca.2012.06.017.

150. Van Herck P., Vanhaecht K., Deneckere S., et al. Key interventions and outcomes in joint arthroplasty clinical pathways: a systematic review. J Eval Clin Pract. 2010 ; 16 (1) : 39–49. doi: 10.1111/j.1365-2753.2008.01111.x.

151. Schmucker A. M., Hupert N., Mandl L. A. The Impact of Frailty on Short-Term Outcomes After Elective Hip and Knee Arthroplasty in Older Adults: A Systematic Review. Geriatr Orthop Surg Rehabil. 2019 ; 10 : 2151459319835109. doi: 10.1177/2151459319835109.

152. Madara K. C., Marmon A., Aljehani M., et al. Progressive rehabilitation after total hip arthroplasty: a pilot and feasibility study. Int J Sports Phys Ther. 2019 ; 14 (4) : 564–581.

153. Heiberg K. E., Ekeland A., Mengshoel A. M. Functional improvements desired by patients before and in the first year after total hip arthroplasty. BMC Musculoskelet Disord. 2013 ; 14 (1) : 243. doi: 10.1186/1471-2474-14-243.

154. Di Monaco M., Castiglioni C. Which type of exercise therapy is effective after hip arthroplasty? A systematic review of Randomized Controlled Trials. Eur J Phys Rehabil Med. 2013 ; 49 (6) : 893–907.

155. Judd D. L., Dennis D. A., Thomas A. C., et al. Muscle strength and functional recovery during the first year after THA. Clin Orthop Relat Res. 2014 ; 472 (2) : 654–664. doi: 10.1007/s11999-013-3136-y.

156. Swanson E. A., Schmalzried T. P., Dorey F. J. Activity recommendations after total hip and knee arthroplasty a survey of the American Association for Hip and Knee Surgeons. J Arthroplasty. 2009 ; 24 (6 Suppl) : 120–126. doi: 10.1016/j.arth.2009.05.014.

157. Petterson S. C., Mizner R. L., Stevens J. E., et al. Improved function from progressive strengthening interventions after total knee arthroplasty: A randomized clinical trial with an imbedded prospective cohort. Arthritis Care Res. 2009 ; 61 (2) : 174–183. doi: 10.1002/art.24167.

158. Dilekçi E, Özkuk K, Kaki B. Effect of balneotherapy on pain and fatigue in elderly with knee osteoarthritis receiving physical therapy: a randomized trial. Int J Biometeorol. 2019 ; 63 (12) : 1555–1568. doi: 10.1007/s00484-019-01768-0.

159. Hahm S. C., Shin H. J., Lee M. G., et al. Mud Therapy Combined with Core Exercise for Chronic Nonspecific Low Back Pain: A Pilot, Single-Blind, Randomized Controlled Trial. Evid Based Complement Alternat Med. 2020 ; 2020 : 7547452. doi: 10.1155/2020/7547452.

160. Bruyère O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019 ; 49 (3) : 337–350. doi: 10.1016/j.semarthrit.2019.04.008.

161. Fuggle N., Laslop A., Rizzoli R., et al. Treatment of Osteoporosis and Osteoarthritis in the Oldest Old. Drugs. 2025 ; 85 (3 ): 343–360. doi: 10.1007/s40265-024-02138-w.

162. Palma Dos Reis R., Giacovelli G., Girolami F., et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J. 2011 ; 5 : 69–77. doi: 10.2174/1874312901105010069.

163. Honvo G., Reginster J. Y., Rabenda V., et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019 ; 36 (Suppl 1) : 65–99. doi: 10.1007/s40266-019-00662-z.

164. Таскина Е. А., Алексеева Л. И., Кашеварова Н. Г., Лила А. М. Длительное многоцентровое наблюдательное исследование препарата Алфлутоп в России: применение у пациентов с остеоартритом коленных суставов (сообщение 4). // Современная ревматология. — 2024. — Т 18, № 4. — С. 80–88. doi: 10.14412/1996-7012-2024-4-80-88.

165. Prabhoo R., Billa G. Undenatured collagen type II for the treatment of osteoarthritis: a review. Int. J. Res. Orthop. 2018 ; 4 (5) : 684–689. doi: 10.18203/issn.2455-4510.IntJResOrthop20183386.

166. Pabst O., Mowat A. M. Oral tolerance to food protein. Mucosal Immunol. 2012 ; 5 (3) : 232–239. doi: 10.1038/mi.2012.4.

167. Jaensson E., Uronen-Hansson H., Pabst O., et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med. 2008 ; 205 (9) : 2139–2149. doi: 10.1084/jem.20080414.

168. Iwata M., Hirakiyama A., Eshima Y., et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004 ; 21 (4) : 527–538. doi: 10.1016/j.immuni.2004.08.011.

169. Weiner H. L., da Cunha A. P., Quintana F, Wu H. Oral tolerance. Immunol Rev. 2011 ; 241 (1) : 241–259. doi: 10.1111/j.1600-065X.2011.01017.x.

170. Kim K. S., Hong S. W., Han D. et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science. 2016 ; 351 (6275) : 858–863. doi: 10.1126/science.aac5560.

171. Kim K. S., Surh C. D. Induction of Immune Tolerance to Dietary Antigens. Adv Exp Med Biol. 2015 ; 850 : 93–118. doi: 10.1007/978-3-319-15774-0_8.

172. Kumar P., Bansal P., Rajnish R. K., et al. Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis. Am J Transl Res. 2023 ; 15 (9) : 5545–5555.

173. Алексеева Л. И., Кашеварова Н. Г., Таскина Е. А. и др. Опыт применения неденатурированного коллагена II типа у пациентов с остеоартритом коленных суставов III стадии: многоцентровое проспективное двойное слепое плацебо-контролируемое рандомизированное исследование (часть II). Терапевтический архив. — 2025. — Т. 97, №1. — C. 54–64. doi: 10.26442/00403660.2025.01.203145.

174. Мазуров В. И., Беляева И. Б., Трофимов Е. А. и др. Сравнение эффективности комбинации неденатурированного коллагена II типа, босвеллиевых кислот, метилсульфонилметана, витаминов С и D3 и комбинации хондроитина сульфата и глюкозамина гидрохлорида в терапии первичного остеоартрита коленного сустава. Терапевтический архив. — 2023. — Т. 95, № 12. — C. 1141–1150. doi: 10.26442/00403660.2023.12.202540.

175. Алексеева Л. И., Кашеварова Н. Г., Таскина Е. А., Стребкова Е. А., Короткова Т. А., Шарапова Е. П., Савушкина Н. М., Лила А. М., Шостак Н. А., Нестерович И. И., Дедкова В. А., Василюк В. Б., Егорова Н. В., Леонтьева М. А., Якупова С. П., Виноградова И. Б., Сороцкая В. Н., Широкова Л. Ю., Рудакова А. В. Опыт применения неденатурированного коллагена II типа у пациентов с остеоартритом коленных суставов III стадии: многоцентровое проспективное двойное слепое плацебо-контролируемое рандомизированное исследование (часть II). Терапевтический архив. 2025;97(1):54–64. doi: 10.26442/00403660.2025.01.203145.

176. Katona G. A clinical trial of glycosaminoglycanpeptide complex ('Rumalon') in patients with osteoarthritis of the knee. Curr Med Res Opin. 1987 ; 10 (9) : 625–633. doi: 10.1185/03007998709112416.

177. Sun C. M., Hall J. A., Blank R. B., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med. 2007 ; 204 (8) : 1775–1785. doi: 10.1084/jem.20070602.